SAGE Therapeutics

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel medicines. It targets diseases and disorders of the brain with three key focus areas: depression, neurology, and neuropsychiatry. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

SAGE Therapeutics poised for Zuranolone launch in 2023, overcoming challenges

SAGE Therapeutics showcased strong financial performance and promising developments with Zuranolone, positioning the drug favorably for potential launch in 2023.
While facing challenges such as enrollment issues and DEA scheduling impacts, the company is leveraging opportunities in commercialization strategies and post-marketing studies to enhance Zuranolone's market presence.
Overall, Zuranolone's rapid and durable effects, alignment with current treatment practices, and targeted commercialization approach present a compelling opportunity for SAGE Therapeutics in the mental health treatment landscape.
By addressing challenges effectively and capitalizing on opportunities, SAGE Therapeutics is poised to make a significant impact in advancing treatments for mood disorders and improving patient outcomes.

Sage Therapeutics reports strong Q1 performance and eyes market expansion

Sage Therapeutics had a strong Q1 2023, focusing on brain health medicines and preparing for zuranolone's launch.
The company's financial position is solid, with growth opportunities in pipeline programs and proactive payer engagements.
Challenges include regulatory uncertainties and competition, but Sage is well-positioned to capitalize on market demand.
Opportunities lie in expanding product indications, proactive agreements with payers, and learning from competitors for strategic advantage.

SAGE Therapeutics to Launch Zurzuvae for Postpartum Depression, Overcomes FDA Setback

SAGE Therapeutics is poised to launch Zurzuvae for postpartum depression, leveraging its financial strength and clinical success. While facing challenges in MDD, the company is strategically adapting to focus on PPD and enhance operational efficiency. Opportunities lie in collaborations, pricing strategies, and addressing the significant market need for PPD treatments.

SAGE Therapeutics advances women's health with ZURZUVAE approval

SAGE Therapeutics navigates financial challenges while advancing innovative treatments for women's health.
ZURZUVAE's approval and commercialization plans present opportunities in a significant market segment.
Strategic focus on engagement, access, and market positioning key to ZURZUVAE's success.
Pipeline advancements and collaboration efforts position SAGE for future growth and impact.

SAGE Therapeutics excels with ZURZUVAE launch, poised for continued growth

SAGE Therapeutics had a strong performance in 2023, driven by the successful launch of ZURZUVAE and positive early market reception.
While facing challenges in data tracking and market competition, the company's focus on innovation and patient access presents growth opportunities.
With a robust pipeline and strategic initiatives in place, SAGE is well-positioned to maintain momentum and drive further success in the brain health space.

SAGE Therapeutics reports strong Zurzuvae launch amidst Parkinson's study setback

SAGE Therapeutics is navigating challenges from the PRECEDENT study while capitalizing on Zurzuvae's successful launch for PPD.
The company's pipeline progress and commitment to addressing cognitive disorders in neurodegenerative diseases showcase a strong focus on brain health.
Collaborative efforts with Biogen, strong payer coverage, and positive market feedback position Zurzuvae as a frontline treatment for PPD.
Strategic initiatives to educate prescribers, expand market reach, and refine study designs present promising growth opportunities for SAGE.

SAGE Therapeutics faces setbacks but sees success with ZURZUVAE in Q2

SAGE Therapeutics navigates setbacks with SAGE-324 study closure but sees success with ZURZUVAE in PPD treatment. Strong financial foundation and commitment to brain health initiatives position the company for future growth.

SAGE Therapeutics focuses on Zurzuvae for PPD treatment success

SAGE Therapeutics prioritizes Zurzuvae for PPD, showing strong revenue growth and prescription uptake
Challenges include discontinuation of certain programs and mixed results in clinical studies
Opportunities lie in focusing resources, upcoming study results, and strategic program ownership
Overall, SAGE's reorganization reflects a strategic shift towards maximizing Zurzuvae's potential

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Sage Therapeutics, Inc. (“Sage” or the “Company”) (NASDAQ: SAGE) investors concerning the Company's possible violations of federal securities laws. On August 4, 2023, Sage disclosed that the U.S. Food and Drug Administration (“FDA”) had approved the New Drug Application (“NDA”) for its postpartum depression (“PPD”) and major depressive disorder (“MDD”) drug, zuranolone, only as a treatment for.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Investors Are Invited To Contact The Schall Law Firm

SAN DIEGO--(BUSINESS WIRE)---- $SAGE #SageTherapeuticsInc--Robbins LLP is Investigating Allegations that Sage Therapeutics, Inc. (SAGE) Misled Investors Regarding the Efficacy of its New Drugs.

Shareholder Rights Attorneys Robbins LLP Reminds SAGE Stockholders of the Opportunity to Lead the Sage Therapeutics, Inc. Class Action

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sage Therapeutics, Inc. (NASDAQ: SAGE) between April 12, 2021 and July 23, 2024, both dates inclusive (the “Class Period”), of the important October 28, 2024 lead plaintiff deadline.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE).

Shareholders that lost money on Sage Therapeutics, Inc. (SAGE) Urged to Join Class Action – Contact The Gross Law Firm to Learn More

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Sage Therapeutics, Inc. (“Sage” or the “Company”) (NASDAQ: SAGE) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 4, 2023, Sage disclosed that the U.S. Food and Drug Administration (“FDA”) had approved the New Drug Application (“NDA”) for its postpartum depression (“PPD”) and.

The Law Offices of Frank R. Cruz Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

The Schall Law Firm Urges Public Participation In A Case For Securities Fraud Against Sage Therapeutics Inc

Korn/Ferry Int.

CLEARWATER, Fla.--(BUSINESS WIRE)--Churchill Stateside Group, LLC (“CSG”), a real estate and renewable energy financial services company, is pleased to announce the closing of Deerwood Apartments, a 144-unit new construction community located in Lake Charles, Louisiana. CSG utilized its PUBLIC-TEL Loan Program to facilitate the closing. The financing includes a $20,840,000 Taxable Construction Loan through Churchill Mortgage Construction, LLC (“CMC”), a $4,800,000 Unfunded Forward Tax-Exempt Pe.

Churchill Stateside Group Closes $47.7MM in Financing for the New Construction of a 144-Unit Apartment Community in Lake Charles, Louisiana

NEW YORK--(BUSINESS WIRE)--Colbeck Capital Management, a leading middle-market private credit firm focused on strategic lending, is pleased to share that Alex Sarver, Head of Investor Relations and Business Development, is attending the Private Debt Investor New York Forum on September 17-18 at the New York Hilton Midtown. The event will gather more than 400 leading investors and fund managers to discuss the latest investment and capital allocation strategies across the private debt asset class.

Colbeck Capital to Attend Private Debt Investor New York Forum 2024

RABAT, Morocco--(BUSINESS WIRE)-- #BLSInternational--BLS International implements robust measures to ensure fair and transparent visa appointment process in Morocco.

BLS International Implements Robust Measures to Ensure Fair and Transparent Visa Appointment Process in Morocco

NEW YORK, NY / ACCESSWIRE / September 9, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=101367&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Sage Therapeutics Inc. May Have Violated Securities Law Violations And Investors Are Encouraged To Contribute To A Lawsuit

SAN DIEGO, CA / ACCESSWIRE / September 9, 2024 / The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. (NASDAQ:SAGE) securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), have until October 28, 2024 to seek appointment as lead plaintiff of the Sage Therapeutics class action lawsuit. Captioned Korver v.

SAGE INVESTOR ALERT: Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, NY / ACCESSWIRE / September 7, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/sage-therapeutics-lawsuit-submission-form?prid=100979&wire=1 or contact Joseph E. Levi, Esq.

Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) Urged to Join Class Action Contact Levi & Korsinsky to Learn More

LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

The Schall Law Firm Invites Sage Therapeutics Inc Shareholders To Partake In A Case For Fraud

SAN DIEGO, Sept. 07, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between April 12, 2021 and July 23, 2024, both dates inclusive (the “Class Period”), have until October 28, 2024 to seek appointment as lead plaintiff of the Sage Therapeutics class action lawsuit. Captioned Korver v. Sage Therapeutics, Inc., No. 24-cv-06511 (S.D.N.Y.), the Sage Therapeutics class action lawsuit charges Sage Therapeutics as well as certain of Sage Therapeutics' top executives with violations of the Securities Exchange Act of 1934.

SAGE INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

A Securities Fraud Lawsuit Has Been Filed Against Sage Therapeutics, Inc. And Investors Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Sage Therapeutics Inc Is Being Sued For Committing Securities Law Violations And The Schall Law Firm Encourages Shareholder Participation

NEWTOWN, Pa. , Sept. 5, 2024 /PRNewswire/ -- Edelson Lechtzin LLP, a leading class action law firm, announces that investors of Sage Therapeutics, Inc. common stock (NASDAQ: SAGE) between April 12, 2021, and July 23, 2024, inclusive (the "Class Period") may seek appointment as lead plaintiff in the pending securities fraud class action lawsuit.

SAGE INVESTOR ALERT: Edelson Lechtzin LLP Urges Sage Therapeutics, Inc. (NASDAQ: SAGE) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Sage business and prospects, resulting in its stock trading at inflated prices.

SAGE INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Sage Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Investors Are Invited To Join The Schall Law Firm In A Securities Fraud Case Against Sage Therapeutics, Inc.

SAN DIEGO, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Sage Therapeutics, Inc. (NASDAQ: SAGE) securities between April 12, 2021 and July 23, 2024.

SAGE Class Action Alert: Robbins LLP Reminds Stockholders of the Sage Therapeutics, Inc. Class Action

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

Securities Fraud Charges Have Been Filed Against Sage Therapeutics Inc And The Schall Law Firm Is Looking For Shareholders Who Want Restitution

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage" or "the Company") (NASDAQ:SAGE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between April 12, 2021 and July 23, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before October 28, 2024.

The Schall Law Firm Encourages Public Participation In A Case Against Sage Therapeutics Inc. For Possible Securities Fraud

SAN DIEGO--(BUSINESS WIRE)---- $SAGE #SAGE--Robbins LLP is Investigating Allegations that Sage Therapeutics, Inc. (SAGE) Misled Investors Regarding the Efficacy of its New Drugs.

News for SAGE Therapeutics Stock (SAGE)